Nonshared Hetero Atoms In At Least Two Rings Of The Polycyclo Ring System Patents (Class 514/81)
-
Publication number: 20100093667Abstract: The invention is related to salts of anti-viral compounds, compositions containing such salts, and therapeutic methods that include the administration of such salts, as well as to processes and intermediates useful for preparing such salts.Type: ApplicationFiled: July 7, 2009Publication date: April 15, 2010Applicant: Gilead Sciences, Inc.Inventors: Benjamin R. Graetz, Richard Polniaszek
-
Publication number: 20100074943Abstract: An object of the invention is to provide a transdermal absorption preparation capable of sustaining the blood morphine concentration at an effective level over at least 48 hours, etc.Type: ApplicationFiled: February 29, 2008Publication date: March 25, 2010Applicant: TEIKA PHARMACEUTICAL CO., LTD.Inventors: Takahito Kimura, Masahiro Orihashi, Shigeto Fujishita, Koichi Takabatake, Tatsuhisa Kato, Satoshi Shiota, Yuichiro Shima
-
Publication number: 20100035841Abstract: Disclosed herein are compounds that inhibit the activity of particular tyrosine kinases. Methods for the preparation of such compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the compounds disclosed, alone or in combination with other therapeutic agents, for the treatment of tyrosine kinase-mediated diseases or conditions or tyrosine kinase-dependent diseases or conditions are provided.Type: ApplicationFiled: October 7, 2009Publication date: February 11, 2010Applicant: Pharmacyclics, Inc.Inventors: Orion D. JANKOWSKI, James T. Palmer, Lee Honigberg
-
Publication number: 20100015190Abstract: The present invention relates to human metabolism, in particular fat reduction and a cosmetic and pharmaceutical formulation, as well as respective uses in particular together with a dressing material according to the invention.Type: ApplicationFiled: August 28, 2007Publication date: January 21, 2010Inventor: Gerard Hassler
-
Publication number: 20100008896Abstract: The present invention relates to a new medical use of fenretinide or bioactive derivatives thereof, particularly to the use of fenretinide or bioactive derivatives thereof in the preparation of a medicament for eliminating or killing tumor stem cells in a subject or for treating and/or preventing a tumor disease originating from tumor stem cells in a subject.Type: ApplicationFiled: July 8, 2008Publication date: January 14, 2010Inventors: Ji Zhang, KanKan Wang, XiaoLing Pan, Hai Fang
-
Publication number: 20100004207Abstract: The invention pertains to novel cyclin dependent kinase inhibitors (cdks) and specifically, but not exclusively, as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell growth and differentiation. Such compounds would be useful for treating subjects having disorders associated with excessive cell proliferation.Type: ApplicationFiled: June 18, 2009Publication date: January 7, 2010Inventors: Nicholas Bockovich, Arthur Kluge, Chris Oalmann, Krishna K. Murthi, Siya Ram, Zhongguo Wang, Jianxing Huang
-
Publication number: 20090325904Abstract: The present invention relates to 3-[({1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl]-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-3?5-phosphanon-1-yl-pivalate maleic acid monosalt, and pharmaceutical composition containing the same.Type: ApplicationFiled: January 11, 2008Publication date: December 31, 2009Applicant: LG Life Sciences Ltd.Inventors: Ji Hye Lee, Ki Sook Park, Jung Min Yun
-
Publication number: 20090324729Abstract: The invention provides a composition comprising, a compound of formula (I): or a pharmaceutically acceptable salt thereof and a plurality of solid carrier particles, as well as methods for using the composition to inhibit the activity of cytochrome P-450.Type: ApplicationFiled: May 1, 2009Publication date: December 31, 2009Applicant: GILEAD SCIENCES, INC.Inventors: Joanna M. Koziara, Mark M. Menning, Reza Oliyai, Robert G. Strickley, Richard Yu, Brian P. Kearney, Anita A. Mathias
-
Publication number: 20090318387Abstract: Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs are described and demonstrated to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents used in the treatment and prevention of various HSP90 mediated disorders. Methods of synthesis and use of such compounds are also described and claimed.Type: ApplicationFiled: May 22, 2009Publication date: December 24, 2009Inventors: Srinivas Rao Kasibhatla, Marco Antonio Biamonte, Jiandong Shi, Marcus F. Boehm
-
Publication number: 20090312288Abstract: Compounds are provided for use with kinases that comprise a compound selected from the group consisting of: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.Type: ApplicationFiled: April 16, 2009Publication date: December 17, 2009Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Jason W. Brown, Qing Dong, Anthony R. Gangloff, Bheema R. Paraselli, Nicholas Scorah, Jeffrey A. Stafford, Sanjib Das, Jonathon S. Salsbury
-
Publication number: 20090298794Abstract: The present invention provides compounds having the following Formula IA and IB, which are useful as MCHR1 antagonists, and includes prodrugs and pharmaceutically acceptable salts thereof:Type: ApplicationFiled: May 28, 2009Publication date: December 3, 2009Inventors: William N. Washburn, Saleem Ahmad, Pratik Devasthale, Jeffrey A. Robl, Animesh Goswami, Zhiwei Guo, Ramesh N. Patel
-
Patent number: 7625881Abstract: Disclosed are prodrugs of A2B adenosine receptor antagonists, having the following structure and their use in treating mammals for various disease states.Type: GrantFiled: June 14, 2006Date of Patent: December 1, 2009Assignee: Gilead Palo Alto, Inc.Inventors: Rao Kalla, Dmitry Koltun, Jeff Zablocki, Elfatih Elzein
-
Publication number: 20090291921Abstract: Tricyclic compounds, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.Type: ApplicationFiled: November 19, 2008Publication date: November 26, 2009Applicant: Gilead Sciences, Inc.Inventors: Salman Y. Jabri, Haolun Jin, Choung U. Kim, Jiayao Li, Samuel E. Metobo, Michael R. Mish
-
Publication number: 20090291922Abstract: Compounds and compositions of Formula I are described, useful as anti-proliferative agents, and in particular anti-HPV, wherein: Y1A and Y1B are independently Y1; RX1 and RX2 are independently RX; Y1 is ?O, —O(RX), ?S, —N(RX), —N(O)(RX), —N(ORX), —N(O)(ORX), or —N(N(RX)(RX)); RX is independently R1, R2, R4, W3, or a protecting group; R1 is independently —H or alkyl of 1 to 18 carbon atoms; R2 is independently R3 or R4 wherein each R4 is independently substituted with 0 to 3 R3 groups or taken together at a carbon atom, two R2 groups form a ring of 3 to 8 carbons and the ring may be substituted with 0 to 3 R3 groups; R3 is R3a, R3b, R3c or R3d, provided that when R3 is bound to a heteroatom, then R3 is R3c or R3d; R3a is —H, —F, —Cl, —Br, —I, —CF3, —CN, N3, —NO2, or —OR4; R3b is ?O, —O(R4), ?S, —N(R4), —N(O)(R4), —N(OR4), —N(O)(OR4), or —N(N(R4)(R4)); R3c is —R4, —N(R4)(R4), —SR4, —S(O)R4, —S(O)2R4, —S(O)(OR4), —S(O)2(OR4), —OC(R3b)R4, —OC(R3b)OR4, —OC(R3b)(N(R4)(R4)), —SC(R3b)R4, —SC(R3b)OR4, —SC(R3b)(Type: ApplicationFiled: May 5, 2009Publication date: November 26, 2009Applicant: Gilead Sciences, Inc.Inventors: Xiaoqin Cheng, Gary P. Cook, Manoj C. Desai, Edward Doerffler, Gong-Xin He, Choung U. Kim, William A. Lee, John C. Rohloff, Jianying Wang, Zheng-Yu Yang
-
Publication number: 20090291908Abstract: This invention provides for a method of synergistically reducing viral load in a patient infected with a virus. The method comprises the oral co-administering an amount of thiophosphonoformic acid and an amount of a nucleoside or nucleotide reverse transcriptase inhibitor in a synergistic combination.Type: ApplicationFiled: March 6, 2006Publication date: November 26, 2009Applicant: Adventrix Pharmaceuticals, Inc.Inventors: Shani Waninger, Joan Robbins, Ramos Silvestri
-
Publication number: 20090275535Abstract: The invention is related to phosphorus substituted compounds with antiviral activity, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: July 1, 2008Publication date: November 5, 2009Inventors: Constantine G. Boojamra, Carina Cannizzaro, James M. Chen, Xiaowu Chen, Aesop Cho, Lee S. Chong, Maria Fardis, Haolun Jin, Ralph F. Hirschmann, Alan X. Huang, Choung U. Kim, Thorsten Kirschberg, Christopher P. Lee, William A. Lee, Richard L. Mackman, David Y. Markevitch, David A. Oare, Vidya K. Prasad, Hyung-Jung Pyun, Adrian S. Ray, Rosemarie Sherlock, Sundaramoorthi Swaminathan, William J. Watkins, Jennifer R. Zhang
-
Publication number: 20090275534Abstract: The invention relates to pyrido[2,3-b]pyrazine compounds of general formulae (Ia) and (Ib), to their preparation and use, for example, for the treatment of malignant disorders and other disorders based on pathological cell proliferations.Type: ApplicationFiled: May 9, 2008Publication date: November 5, 2009Applicant: ZENTARIS GmbHInventors: Matthias Gerlach, Irene Seipelt, Eckhard Guenther, Emmanuel Polymeropoulos, Tilmann Schuster, Eckhard Claus
-
Publication number: 20090275536Abstract: Described herein are antibacterial compounds, methods for making the compounds, pharmaceutical compositions containing the compounds and methods of treating bacterial infections utilizing the compounds and pharmaceutical composition.Type: ApplicationFiled: July 15, 2009Publication date: November 5, 2009Inventors: Timothy A. Johnson, Dennis J. McNamara, Debra A. Sherry, Peter Laurence Toogood
-
Publication number: 20090270352Abstract: The present invention provides a novel crystalline form of Tenofovir disoproxil fumarate (Tenofovir DF), designated Co-crystal TDFA 2:1, methods for the preparation thereof and its use in pharmaceutical applications, in particular in anti-HIV medicaments. The crystalline form TDFA 2:1 can be used in combination with other anti-HIV medicaments such as Efavirenz, Emtricitabine, Ritonavir and/or TMC114.Type: ApplicationFiled: May 21, 2008Publication date: October 29, 2009Applicant: ULTIMORPHIX TECHNOLOGIES B.V.Inventors: Evanthia Dova, Jaroslaw Marek Mazurek, Johnny Anker
-
Patent number: 7608603Abstract: Compounds of formula Ia, Ib, Ic, Id, Ie, If, Ig or Ih: wherein X and Y are nitrogen or one of X and Y is nitrogen and the other is CRg, and W, D, E, R4, R5, R6 and Rg are as defined herein. Also disclosed are methods of making the subject compounds and methods of using the compounds in the treatment of p38 MAP kinase-mediated diseases.Type: GrantFiled: August 23, 2006Date of Patent: October 27, 2009Assignee: Roche Palo Alto LLCInventors: Nolan James Dewdney, Tobias Gabriel, Kristen Lynn McCaleb
-
Patent number: 7605147Abstract: The present invention relates to an acyclic nucleoside phosphonate derivative represented by the following formula (1): in which represents single bond or double bond, R1, R2, R3, R7 and R8 are defined herein, Y represents —O—, —S—, —CH(Z)-, ?C(Z)-, —N(Z)-, ?N—, or —SiH(Z)-, wherein Z represents hydrogen, hydroxy or halogen, or represents C1-C7-alkyl, C1-C5-alkoxy, allyl, hydroxy-C1-C7-alkyl, C1-C7-aminoalkyl or phenyl, Q represents a group having the following formula: wherein X1, and X2 independently of one another represent hydrogen, amino, hydroxy or halogen, or represent C1-C7-alkyl, C1-C5-alkoxy, allyl, hydroxy-C1-C7-alkyl, phenyl or phenoxy each of which is optionally substituted by nitro or C1-C5-alkoxy, or represent C6-C10-arylthio which is optionally substituted by nitro, amino, C1-C6-alkyl or C1-C4-alkoxy, or represent C6-C12-arylamino, C1-C7-alkylamino, di(C1-C7-alkyl)amino, C3-C6-cycloalkylamino or a structure of wherein n denotes an integer of 1 or 2 and Y1 represents O, CH2 or N—Type: GrantFiled: June 20, 2006Date of Patent: October 20, 2009Assignee: LG Life Sciences Ltd.Inventors: Dong-Gyu Cho, Jae-Hong Lim, Jae-Taeg Hwang, Woo-Young Cho, Hyun-Sook Jang, Chang-Ho Lee, Tae-Saeng Choi, Chung-Mi Kim, Yong-Zu Kim, Tae-Kyun Kim, Seung-Joo Cho, Gyoung-Won Kim, Jong-Ryoo Choi, Jeong-Min Kim, Kee-Yoon Roh
-
Publication number: 20090258840Abstract: A compound of formula (1), and/or its salts, tautomers or solvates is used to treat hematological malignancies. In an embodiment, an organic acid salt of compound 1 is provided for general use in treatment of neoplasms, and in a further embodiment the salt is stabilized with carbohydrate.Type: ApplicationFiled: May 16, 2007Publication date: October 15, 2009Applicant: Gilead Sciences, Inc.Inventors: Lee S. Chong, William S. Lee, Adrian S. Ray, Hans Reiser, Daniel B. Tumas, William J. Watkins
-
Publication number: 20090253654Abstract: The present invention refers to compounds that, in addition to enhancing the sensitivity to acetylcholine and choline, and their exogenous agonists, of neuronal cholinergic receptors and/or acting as cholinesterase inhibitors and/or neuroprotective agents, have enhanced blood-brain barrier permeability in comparison to their parent compounds. The compounds are derived (either formally by their chemical structure or directly by chemical synthesis) from natural compounds belonging to the class of amaryllidaceae alkaloids e.g., galantamine, narwedine and lycoramine, or from metabolites of said compounds. The compounds of the present invention can either interact as such with their target molecules, or they can act as “pro-drugs”, in the sense that after reaching their target regions in the body they are converted by hydrolysis or enzymatic attack to the original parent compound and react as such with their target molecules, or both. The compounds of this invention may be used as medicaments.Type: ApplicationFiled: April 13, 2009Publication date: October 8, 2009Applicant: GALANTOS PHARMA GMBHInventor: Alfred Maelicke
-
Publication number: 20090247487Abstract: The present invention is directed to a method for treating hepatitis B virus infection in humans comprising administering a synergistically effective amount of agents having known anti-hepatitis B virus activity in combination or alternation. Specifically, the invention is directed to a method for treating hepatitis B virus infection comprising administering FTC in combination or alternation with penciclovir, famciclovir or Bis-POM-PMEA. Additionally, the invention is directed to a method for treating hepatitis B virus infection comprising administering L-FMAU in combination or alternation with DAPD, penciclovir or Bis-POM-PMEA. The invention is further directed to a method for treating hepatitis B virus infection comprising administering DAPD in combination or alternation with Bis-POM-PMEA.Type: ApplicationFiled: June 12, 2009Publication date: October 1, 2009Applicant: GILEAD SCIENCES, INC.Inventors: Phillip A. Furman, George R. Painter, III, David W. Barry, Franck Rousseau
-
Publication number: 20090232768Abstract: Novel compounds having structure (1) wherein Z, Y, R1, R2? and R2 are defined in the specification, are provided for use in the treatment of tumors and the prophylaxis or treatment of viral infections.Type: ApplicationFiled: February 19, 2009Publication date: September 17, 2009Applicant: Gilead Sciences, Inc.Inventors: Gabriel Birkus, Andrian S. Ray, Daniel B. Tumas, William J. Watkins
-
Publication number: 20090233882Abstract: The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis employing. The methods and compositions employ guanosine 3?,5?-cyclic monophosphate pharmaceutically acceptable salt thereof.Type: ApplicationFiled: November 22, 2006Publication date: September 17, 2009Applicant: IRONWOOD PHARMACEUTICALS, INC.Inventor: Mark G. Currie
-
Publication number: 20090221671Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of LMW-PTPase in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Also provided are methods for the prevention, amelioration and/or treatment of diabetes, insulin resistance, insulin deficiency, hypercholesterolemia, hyperglycemia, dyslipidemia, hyperlipidemia, hypertriglyceridemia, and hyperfattyacidemia. In some embodiments, the diabetes is type II diabetes by administration of antisense compounds targeted to LMW-PTPase.Type: ApplicationFiled: May 24, 2006Publication date: September 3, 2009Inventors: Sanjay Pandey, Robert McKay, Sanjay Bhanot, Xing-Xian Yu
-
Publication number: 20090215726Abstract: Compounds and compositions are provided for treatment, prevention, or amelioration of a variety of medical disorders associated with viral infections and/or cell proliferation. The compounds provided herein are 5-phosphono-pent-2-en-1-yl nucleosides and esters thereof.Type: ApplicationFiled: March 30, 2006Publication date: August 27, 2009Inventors: Karl Y. Hosterler, James R. Beadle, Hyunah Choo
-
Patent number: 7579325Abstract: The present invention provides medicines for preventing or treating infectious diseases, sepsis and/or septic shock, which exhibit excellent immunostimulating effects. More specifically, the invention provides medicines for immunostimulation and infection-protection and -treatment, and/or for preventing or treating sepsis and septic shock, which comprise reduced riboflavin and/or reduced riboflavin derivative or pharmacologically acceptable salt thereof. Also provided are methods for using them in the prevention and/or treatment of infectious disorders such as sepsis and septic shock.Type: GrantFiled: March 19, 2002Date of Patent: August 25, 2009Assignee: Eisai R & D Management Co., Ltd.Inventors: Seiichi Araki, Mamoru Suzuki, Yoshiki Sugihara, Toshio Toyosawa
-
Patent number: 7579354Abstract: The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable.Type: GrantFiled: July 10, 2006Date of Patent: August 25, 2009Inventors: William F. Kiesman, Carol L. Ensinger, Russell C. Petter, James E. Dowling, Gnanasambandam Kumaravel, He Xi Chang, Ko Chung Lin
-
Patent number: 7579332Abstract: The invention provides compounds with activity against infectious diseases. The compounds of the invention may inhibit retroviral reverse transcriptases and thus inhibit the replication, of the virus. The compounds of the invention may be useful for treating human patients infected with a human retrovirus, such as human immunodeficiency virus (strains of HIV-l or HIV-2) or human T-cell leukemia virus (HTLV-1 or HTLV-II) which results in acquired immunodeficiency syndrome (AIDS) and/or related diseases.Type: GrantFiled: July 30, 2004Date of Patent: August 25, 2009Assignee: Gilead Sciences, Inc.Inventor: Steven H. Krawczyk
-
Publication number: 20090209625Abstract: Disclosed herein are compounds, compositions, and methods for modulating the expression of ChREBP in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and conditions.Type: ApplicationFiled: May 23, 2007Publication date: August 20, 2009Inventors: Sanjay Bhanot, Kenneth W. Dobie, Susan F. Murray
-
Publication number: 20090203646Abstract: The present invention concerns a method for reducing or preventing development of adhesions, fibrosis or scar tissue within serous body cavities by using sodium narcistatin.Type: ApplicationFiled: February 12, 2009Publication date: August 13, 2009Inventors: Cheri Lubahn, Dianne Lorton
-
Publication number: 20090202484Abstract: The present application provides for a compound of Formula (I) or (II): or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods that include the administration of such compounds with at least one additional active agent.Type: ApplicationFiled: July 6, 2007Publication date: August 13, 2009Applicant: Gilead Sciences, Inc.Inventors: Lee S. Chong, Manoj C. Desai, Brian Gallagher, Michael Graupe, Randall L. Halcomb, Hong Yang, Jennifer R. Zhang
-
Patent number: 7566721Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.Type: GrantFiled: August 3, 2006Date of Patent: July 28, 2009Assignee: OSI Pharmaceuticals, Inc.Inventors: Qun-Sheng Ji, Mark Joseph Mulvihill, Arno G. Steinig, Qinghua Weng
-
Patent number: 7563781Abstract: The invention relates to the discovery of triazolopyrimidine derivatives of formula (I), which have been found to exhibit inhibitory activity against the serine-tyrosine and tyrosine kinases.Type: GrantFiled: January 11, 2006Date of Patent: July 21, 2009Assignee: Janssen Pharmaceutica NVInventors: Donald W. Ludovici, Richard W. Connors, Steven J. Coats, Li Liu, Bart L. De Corte, Dana L. Johnson, Mark J. Schulz
-
Publication number: 20090176743Abstract: The invention is directed to methods and compositions for treating or preventing reactivation of a latent herpesvirus infection and the associated complications and outcomes. The methods involve administering a composition comprising glutamine, or a derivative, conjugate, or analog thereof.Type: ApplicationFiled: July 31, 2006Publication date: July 9, 2009Inventors: Priscilla Schaffer, Ryan Bringhurst
-
Publication number: 20090176742Abstract: The invention provides ?-mimetic structure of formula (I), wherein A is —(C?O)—(CHR3)— or —(C?O)—; B is —(NR5)— or —(CHR6)—; D is —(C?O)—(CHR7)— or —(C?O)—; E is -(ZR8)— or —(C?O)—, where Z is nitrogen or CH; —(XR9)n—, —(CHR10)—(NR6)—, —(C?O)—(XR12)—, —(C?N—W—R1)—, —(C?O)—, —(X—(C?O)—R13)—, —(X—(C?O)—NR13R14)—, —(X—(SO2)—R13)—, or —(X—(C?O)—OR13)—, where X is nitrogen or CH, and n=0 or 1; W is —Y(C?O)—, —(C?O)—(NH)—, —(SO2)—, —(CHR14)—, —(C?O)—(NR15)—, substituted or unsubstituted oxadiazole, substituted or unsubstituted triazole, substituted or unsubstituted thiadiazole, substituted or unsubstituted 4,5-dihydrooxazole, substituted or unsubstituted 4,5-dihydrothiazole, substituted or unsubstituted 4,5-dihydroimidizole, or nothing, where Y is oxygen or sulfur; and R1, R2, R3, R4, R5, R6, R7, R8, R9 R10, R11, R12, R13, R14, and R15 are the same or different and independently selected from an amino acid side chain moiety or derivative thereof, the remainder of the molecule, a linker and a solid support, and sterType: ApplicationFiled: September 25, 2007Publication date: July 9, 2009Applicants: UNIVERSITY OF WASHINGTON, INSTITUTE FOR CHEMICAL GENOMICSInventors: William R. HENDERSON, Michael KAHN
-
Patent number: 7553825Abstract: Compounds and compositions of Formula I are described, useful as anti-proliferative agents, and in particular anti-HPV, wherein: Y1A and Y1B are independently Y1; RX1 and RX2 are independently RX; Y1 is ?O, —O(RX), ?S, —N(RX), —N(O)(RX), —N(ORX), —N(O)(ORX), or —N(N(RX) (RX)); RX is independently R1, R2, R4, W3, or a protecting group; R1 is independently —H or alkyl of 1 to 18 carbon atoms; R2 is independently R3 or R4 wherein each R4 is independently substituted with 0 to 3 R3 groups or taken together at a carbon atom, two R2 groups form a ring of 3 to 8 carbons and the ring may be substituted with 0 to 3 R3 groups; R3 is R3a, R3b, R3c or R3d, provided that when R3 is bound to a heteroatom, then R3 is R3c or R3d; R3a is —H, —F, —Cl, —Br, —I, —CF3, —CN, N3, —NO2, or —OR4; R3b is ?O, —O(R4), ?S, —N(R4), —N(O)(R4), —N(OR4), —N(O)(OR4), or —N(N(R4) (R4)); R3c is —R4, —N(R4)(R4), —SR4, —S(O)R4, —S(O)2R4, —S(O)(OR4), —S(O)2(OR4), —OC(R3b)R4, —OC(R3b)OR4, —OC(R3b)(N(R4)(R4)), —SC(R3b)R4, —SC(R3b)OR4, SC(R3b)Type: GrantFiled: December 29, 2004Date of Patent: June 30, 2009Assignee: Gilead Sciences, Inc.Inventors: Xiaoqin Cheng, Gary P. Cook, Manoj C. Desai, Edward Doerffler, Gong-Xin He, Choung U. Kim, William A. Lee, John C. Rohloff, Jianying Wang, Zheng-Yu Yang
-
Publication number: 20090156557Abstract: Compounds are provided for use with kinases that comprise a compound selected from the group consisting of: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.Type: ApplicationFiled: April 15, 2008Publication date: June 18, 2009Applicant: TAKEDA SAN DIEGO, INC.Inventors: Jason W. Brown, Qing Dong, Bheema R. Paraselli, Jeffrey A. Stafford, Xianchang Gong, Yan Liu, Nicholas Scorah, Michael B. Wallace
-
Publication number: 20090156545Abstract: Compounds and compositions are provided for treatment, prevention, or amelioration of a variety of medical disorders associated with viral infections and/or cell proliferation. The compounds provided herein are obtained by attaching the phosphonate nucleoside of interest to alkyloxyalkyl-phosphate or alkyl-phosphate in a phosphate-phosphono anhydride linkage to provide a modified nucleoside phosphonate drug.Type: ApplicationFiled: March 30, 2006Publication date: June 18, 2009Inventors: Karl Y. Hostetler, James R. Beadle, Jacqueline C. Ruiz
-
Publication number: 20090156558Abstract: The invention is related to phosphorus substituted antimetabolites, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: July 2, 2008Publication date: June 18, 2009Inventors: Maria Fardis, Thorsten Kirschberg, William J. Watkins
-
Publication number: 20090149400Abstract: Compounds and compositions of Formula I are described, useful as anti-proliferative agents, and in particular anti-HPV, wherein: Y1A and Y1B are independently Y1; RX1 and RX2 are independently RX; Y1 is ?O, —O(RX), ?S, —N(RX), —N(O)(RX), —N(ORX), —N(O)(ORX), or —N(N(RX)(RX)); RX is independently R1, R2, R4, W3, or a protecting group; R1 is independently —H or alkyl of 1 to 18 carbon atoms; R2 is independently R3 or R4 wherein each R4 is independently substituted with 0 to 3 R3 groups or taken together at a carbon atom, two R2 groups form a ring of 3 to 8 carbons and the ring may be substituted with 0 to 3 R3 groups; R3 is R3a, R3b, R3c or R3d, provided that when R3 is bound to a heteroatom, then R3 is R3c or R3d; R3a is —H, —F, —Cl, —Br, —I, —CF3, —CN, N3, —NO2, or —OR4; R3b is ?O, —O(R4), ?S, —N(R4), —N(O)(R4), —N(OR4), —N(O)(OR4), or —N(N(R4)(R4)); R3c is —R4, —N(R4)(R4), —SR4, —S(O)R4, —S(O)2R4, —S(O)(OR4), —S(O)2(OR4), —OC(R3b)R4, —OC(R3b)OR4, —OC(R3b)(N(R4)(R4)), —SC(R3b)R4, —SC(R3b)OR4, —SC(R3b)(Type: ApplicationFiled: February 18, 2009Publication date: June 11, 2009Applicant: Gilead Sciences, Inc.Inventors: Xiaoqin Cheng, Gary P. Cook, Manoj C. Desai, Edward Doerffler, Gong-Xin He, Choung U. Kim, William A. Lee, John C. Rohloff, Jianying Wang, Zheng-yu Yang
-
Patent number: 7544672Abstract: Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs are described and demonstrated to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents used in the treatment and prevention of various HSP90 mediated disorders. Methods of synthesis and use of such compounds are also described and claimed.Type: GrantFiled: March 29, 2006Date of Patent: June 9, 2009Assignee: Conforma Therapeutics CorporationInventors: Srinivas Rao Kasibhatla, Marco Antonio Biamonte, Jiandong Shi, Marcus F. Boehm
-
Publication number: 20090143314Abstract: The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R, 5S, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva™, (-)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.Type: ApplicationFiled: August 20, 2008Publication date: June 4, 2009Applicant: Gilead Sciences, Inc.Inventors: Terrence C. Dahl, Mark M. Menning, Reza Oliyai
-
Publication number: 20090143335Abstract: The present invention relates to a pharmaceutical composition comprising gaboxadol or a pharmaceutically acceptable salt thereof and one or more inhibitors of PAT1 and/or one or more inhibitors of OAT. The present invention further relates to a pharmaceutical composition comprising from about 0.5 mg to about 50 mg gaboxadol or a pharmaceutically acceptable salt thereof, wherein the composition provides an in vivo plasma profile comprising a mean Tmax which is longer than about 20 minutes.Type: ApplicationFiled: October 17, 2008Publication date: June 4, 2009Applicant: H. LUNDBECK A/SInventors: Mie Larsen, Carsten Uhd Nielsen, Birger Brodin Larsen, Rene Holm
-
Publication number: 20090131370Abstract: Compounds of Formulae I-XVI, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of viral diseases including hepatitis C viral infection, cancer, diabetes, and other diseases are described: formula (I).Type: ApplicationFiled: July 29, 2005Publication date: May 21, 2009Applicant: METABASIS THERAPEUTICS , INC.Inventors: K. Raja Reddy, Mark D. Erion
-
Publication number: 20090124580Abstract: The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.Type: ApplicationFiled: November 10, 2008Publication date: May 14, 2009Inventors: Rajinder Singh, Somasekhar Bhamidipati, Esteban Masuda
-
Publication number: 20090118233Abstract: A heterocyclic compound of the formula (I): wherein B1 is —C(R2)? or —N?; R1? is H, etc.; one of R1 and R2 is -Z1-Z2-Z3-R5 wherein Z1 and Z3 are independently single bond, optionally substituted alkylene, etc.; Z2 is single bond, optionally substituted alkylene, etc.; R5 is optionally substituted aryl, optionally substituted heteroaryl, etc., and the other of R1 and R2 is H; -A1- is —C(—Y)?C(—RA)—C(—R3)?C(—R4)—, etc. wherein Y is OH, etc.; RA is —COR7 wherein R7 is OH, etc.; one of R3 and R4 is carboxy, etc., and the other of R1 and R2 is H, etc, a prodrug thereof, a pharmaceutically acceptable salt thereof, and a solvate thereof, having an antiviral activity, more particularly, an inhibitory activity against HIV integrase, and a pharmaceutical composition containing the same, especially an anti-HIV drug.Type: ApplicationFiled: February 26, 2008Publication date: May 7, 2009Inventors: Hitoshi Murai, Takeshi Endo, Noriyuki Kurose, Teruhiko Taishi, Hiroshi Yoshida
-
Patent number: 7528121Abstract: Quinazoline derivatives of formula (I) wherein A is 5-membered heteroaryl containing a nitrogen atom and one or two further nitrogen atoms; compositions containing them, processes for their preparation and their use in therapy.Type: GrantFiled: December 22, 2003Date of Patent: May 5, 2009Assignee: AstraZeneca ABInventors: Nicola Murdoch Heron, Andrew Austen Mortlock